Italia markets closed

Sanofi (SAN.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
85,39-0,55 (-0,64%)
Alla chiusura: 05:36PM CET
Schermo intero
Chiusura precedente85,94
Aperto86,08
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno85,35 - 86,54
Intervallo di 52 settimane76,45 - 106,66
Volume1.602.061
Media Volume1.875.817
Capitalizzazione110,351B
Beta (5 anni mensile)0,42
Rapporto PE (ttm)16,74
EPS (ttm)5,10
Prossima data utili28 ott 2022
Rendimento e dividendo (forward)3,33 (3,88%)
Data ex dividendo06 mag 2022
Stima target 1A99,98
  • GlobeNewswire

    Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules

    THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "TAKEOVER RULES"). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DECEMBER 2, 2022 Statement from Sanofi regarding: rule 2.12 of the takeover rules Paris, December 2, 2022. As required by Rule 2.12 of the Takeover Rules, Sanofi S.A.

  • GlobeNewswire

    Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

    Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease Geneva, Kinshasa, Paris – November 30, 2022. The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigati

  • GlobeNewswire

    Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

    European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has granted marketing authorization for Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chr